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Abstract
While Lymphotoxin α (TNF-β), a product of lymphocytes, is known to play a pivotal role in
inflammatory joint environment, resveratrol has been shown to possess anti-inflammatory
and chondroprotective effects via activation of the histondeacetylase Sirt1. Whether TNF-β
induction of inflammatory pathways in primary human chondrocytes (PCH) can be modu-
lated by resveratrol, was investigated. Monolayer and alginate cultures of PCH were treated
with TNF-β, anti-TNF-β, nicotinamide (NAM), antisense oligonucleotides against Sirt1
(Sirt1-ASO) and/or resveratrol and co-cultured with T-lymphocytes. We found that resvera-
trol suppressed, similar to anti-TNF-β, TNF-β-induced increased adhesiveness in an inflam-
matory microenvironment of T-lymphocytes and PCH. In contrast, knockdown of Sirt1 by
mRNA abolished the inhibitory effects of resveratrol on the TNF-β-induced adhesiveness,
suggesting the essential role of this enzyme for resveratrol-mediated anti-inflammatory sig-
naling. Similar results were obtained in PCH stimulated with TNF-α. Sirt1-ASO, NAM or
TNF-β, similar to T-lymphocytes induced inflammatory microenvironment by down-regula-
tion of cartilage-specific proteins, Sox9, Ki67 and enhanced NF-κB-regulated gene products
involved in inflammatory and degradative processes in cartilage (MMP-9/-13, COX-2, cas-
pase-3), NF-κB activation and its translocation to the nucleus. Moreover, resveratrol
reversed the TNF-β-, NAM-, T-lymphocytes-induced up-regulation of various NF-κB-regu-
lated gene products. Down-regulation of Sirt1 by mRNA interference abrogated the effect of
resveratrol on TNF-β-induced effects. Ultrastructural and cell viability assay investigations
revealed that resveratrol revoked TNF-β-induced dose-dependent degradative/apoptotic
morphological changes, cell viability and proliferation in PCH. Taken together, suppression
of TNF-β-induced inflammatory microenvironment in PCH by resveratrol/Sirt1 might be a
novel therapeutic approach for targeting inflammation during rheumatoid arthritis.
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Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disorder charac-
terized by inflammation and degeneration of the synovial joints affecting in particular, the car-
tilage and the underlying bone [1]. In industrialised countries, RA is the most common
inflammatory arthritis affecting 0.5–1% of adults, with 5–50 per 100000 new cases annually
and occurring typically in women and elderly people [2]. To date, a well characterized key
inflammatory cascade in RA is overproduction and overexpression of TNF-α, enhancing
interactions between T- and B-lymphocytes, synovial-like fibroblasts and macrophages, lead-
ing to synovial inflammation and joint destruction [3] and further promoting overexpression,
release and activity of pro-inflammatory cytokines such TNF-α, vascular endothelial growth
factor (VEGF), Interleukin-1β (IL-1β), IL-6, IL-8 and IFN-γ [4, 5]. In response to these pro-
inflammatory stimuli, NF-κB-dependently matrix metalloproteinases (MMPs) and cyclooxy-
genase-2 (COX-2) are produced, progressively degrading the cartilage [6, 7]. Interestingly, it
has been previously reported that lymphotoxin α (LT-α) alias TNF-β, another member of the
TNF superfamily, may play a critical role in RA [8]. Moreover, TNF-β is the closest homolog
to TNF-α showing 35% identity and 50% homology to TNF-α at amino acid sequences and
structural similarity in tertiary and quaternary structure indicating similar biological activity
[9, 10]. More interestingly, TNF-β is expressed by a variety of cells, including T-cells, B-cells
and natural killer (NK) cells [11]. Studies have indicated that TNF-β levels are elevated in the
serum and synovial tissue of RA patients and that TNF-β stimulates proliferation and inflam-
matory cascade signaling in synovial-fibroblasts [8, 12, 13]. Our group could previously show
in vitro that TNF-β is involved in microenvironment inflammation in chondrocytes similar to
IL-1β, resulting in the up-regulation of NF-κB signaling and this could be suppressed by the
natural NF-κB inhibitor, curcumin [14].
Disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate or biological
agents such TNF-inhibitors, reduce synovitis and systemic inflammation and improve func-
tion [2]. However, they are more often accompanied with severe side effects. In the search for
novel effective and safe RA therapies, natural compounds have demonstrated great ability to
suppress inflammatory processes through inhibition of pro-inflammatory cytokines. The natu-
ral polyphenol resveratrol (3,5,4´-trihydroxy-trans-stilbene), found in the skin of red grapes,
cranberries, peanuts and root extracts of the weed Polygonum cuspidatum, functions microbio-
logically as a phytoalexin protecting plants against fungal infections and UV radiation [15]. It
has been found to possess a wide range of biological and pharmacological activities including
anti-oxidative, anti-inflammatory, anti-mutagenic and anti-carcinogenic effects [16]. One of
the most important molecular targets of resveratrol is sirtuin-1 (Sirt1), a member of the sirtuin
family of nicotinamide adenine dinucleotide (NAD)-dependent deacetylases [17]. The sirtuin
family consists of Sirt1-7 and shares a highly conserved NAD+-binding catalytic core domain
although they exhibit distinct expression patterns, catalytic activities and biological functions
[18]. Being able to de-acetylate a wide range of different targets in the cytoplasm and nucleus
such as transcription factors p53, Ku70, NF-κB, forkhead proteins, nuclear receptor PPARγ
and PGC-α. Indeed, Sirt1 plays an essential role in cell differentiation, cell survival, tumorigen-
esis, inflammation and metabolism [18–20].
Studies from our laboratory have previously shown that resveratrol possesses anti-inflam-
matory and chondroprotective effects in human chondrocytes in vitro [21–23]. Indeed, resver-
atrol treatment significantly upregulates Sirt1 expression in normal and osteoarthritic (OA)
chondrocytes [24, 25]. Further, in an OA mouse model intra-articular injection of resveratrol
significantly prevented the destruction of cartilage by activating Sirt1 [26]. Inflammatory
TNFα-induced overexpression of Sirt1 was found to be constitutively upregulated in synovial
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tissues and cells from patients with RA compared to OA contributing to chronic inflammation
and inhibiting apoptosis [27]. Contrary to this, in chondrocytes, TNF-α-induced Sirt1-inacti-
vation correlated with reduced cartilage-specific gene expression [28] and it is widely accepted
that Sirt1 exerts positive effects on cartilage by encouraging chondrocyte survival, especially
under stress conditions [29].
Several lines of evidence have shown that normal cartilage homeostasis requires enzymati-
cally active Sirt1 protein in vivo [30–32]. In fact, decrease of Sirt1 expression was noted during
development of OA and reduction of Sirt1 in chondrocytes correlated with enhanced chon-
drocyte hypertrophy and cartilage matrix loss [33]. Indeed, it has been shown that antagonistic
crosstalk between Sirt1 and NF-κB signaling suppresses inflammation, maintains normal bone
remodeling, chondrocytes homeostasis and inhibits apoptosis [25, 34–37]. In TNF-α-induced
inflammation, Sirt1 deacetylated and inactivated NF-κB, thereby exerting its anti-inflamma-
tory effect in chondrocytes [38]. Further, reports show that Sirt1 plays a protective role by sup-
pressing IL-1β- or TNF-β-induced expressions of cartilage-degrading enzymes by modulation
of the NF-κB pathway and NF-κB-dependent-gene-end-products [25, 39]. However, the role
of resveratrol induced Sirt1-activation during TNF-β-induced inflammatory environment in
RA/OA is widely unknown and needs to be further elucidated.
The purpose of this study was therefore, to examine the effect of resveratrol-induced Sirt1
signalling on suppressing inflammatory pathways activated by TNF-β in primary human
chondrocytes as potential novel therapeutic approach for the treatment of inflammatory joint
diseases such as RA/OA.
Materials and methods
Antibodies and cytokines
Anti-active caspase-3, -MMP-9, -MMP-13, -TNF-α and TNF-α were purchased from R&D
Systems, Inc., (Heidelberg, Germany). Antibodies to phospho-specific p65 (NF-κB)/(Ser536)
were purchased from Cell Technology (Beverly, MA, USA). Antibodies to collagen type II and
alkaline phosphatase-linked sheep anti-mouse and sheep anti-rabbit secondary antibodies for
immunoblotting were purchased from Millipore (Schwalbach, Germany). Anti-TNF-β was
obtained from eBioscience (Frankfurt, Germany). Anti-Ki67 and secondary antibodies used
for fluorescence labelling were purchased from Dianova (Hamburg, Germany). Anti-cyclooxy-
genase-2 was purchased from Cayman Chemical (Ann Arbor, MI, USA). Monoclonal anti-β-
Actin was obtained from Sigma-Aldrich (Munich, Germany). Sox9 antibody was purchased
from Acris Antibodies GmbH (Hiddenhausen, Germany). Polyclonal antibody against Sirt1
was purchased from Abcam PLC (Cambridge, UK).TNF-β and polyclonal rabbit anti-TNF-β
were obtained as described [40]. Bacteria-derived recombinant human TNF-α and LT-α
(TNF-β), both purified to homogeneity with a specific activity of 50 million units/mg, were
kindly gift from Genentech, Inc. (South San Francisco, CA).
Growth media and chemicals
Cell culture growth medium was prepared as previously described [25]. Dulbecco’s modified
Eagle’s medium/Ham’s F-12 (1:1), 10% fetal bovine serum (FBS), 0,5% amphotericin B solu-
tion, 1% penicillin/streptomycin solution (10,000 IU/10,000 IU), 75 μg/ml ascorbic acid, 1%
essential amino acids and 1% glutamine was obtained from Seromed (Munich, Germany).
Epon was purchased from Plano (Marburg, Germany). Alginate, Nicotinamide (NAM) and
resveratrol with purity greater than 98% were purchased from Sigma (Munich, Germany). A
100mM stock solution of resveratrol (molecular weight 228.2) was prepared in ethanol and
further diluted in cell culture medium to prepare working concentrations. The maximum final
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content of ethanol in cultures was less than 0.1%. This concentration was also used as a con-
trol. The stock solution was stored at -20˚C.
Chondrocyte and T-lymphocyte culture
Primary human chondrocytes (HCHON, catalog no. 121 0211) were purchased from Provitro
(Berlin, Germany). Cartilage samples of knee joint used for chondrocyte isolation were derived
from human patient (50 years old, female undergoing total knee replacement), who provided
her full informed consent. Participant gave written informed consent. This study was carried
out in accordance with the declaration of Helsinki and local ethics committee approval was
provided by the Charite´-University Medical School Berlin, Germany. Briefly, during mono-
layer expansion, chondrocytes were seeded at a density of 300,000 cells/T75 cell culture flask
and grown until 70% confluence was reached in cell culture growth medium (10% FBS).
Chondrocytes were passaged up to two times, and passages 2 and 3 were used in the experi-
ments. Chondrocytes were washed three times with serum-starved medium (3% FBS) and fur-
ther incubated for 30 minutes with the same medium before initiation of experiments. All
experiments were performed with serum-starved medium. A human T-lymphocyte cell line
(Jurkat cells) [41] was cultured in suspension with whole-cell culture growth medium as
described above.
Antisense and Lipofectin-mediated transfection in chondrocytes
Transient transfection of primary human chondrocytes was performed as previously described
in detail [25, 42]. The Sirt1 antisense sequences used in these experiments were designed using
a computational neural network mode [43]. Briefly, Phosphorothioate-specific oligonucleo-
tides (21-mer) in antisense (ASO) (sequence 5´-GTATTCCACATGAAACAGACA-3´) corre-
sponding to Sirt1 mRNA and control 21-mer sense oligonucleotides (SO) (sequence 5´-TG
TCTGTTTCATGTGGAATAC-3 )´ were synthesized by eurofins (mwg/operon, Ebersberg, Ger-
many). All ASOs and SOs were phosphorothioate-modified to protect them from cell nucle-
ases. Transfection was carried out by incubating the primary chondrocytes in monolayer
culture for 24h with 0.5μM ASO against Sirt1 or SO control and 10μl/ml Lipofectin transfec-
tion reagent (Invitrogen, Carlsbad, CA, USA) in serum-starved medium before starting the
respective experiments. All transfection experiments were carried out on 50% confluent
monolayer cultures.
Adhesion assay interaction of chondrocytes with T-lymphocytes
For investigation of interaction between chondrocytes with T-lymphocytes an adhesion assay
was performed as previously described [14]. Briefly, primary human chondrocytes were grown
to subconfluence in monolayer culture and either left untreated alone or co-cultured with T-
lymphocytes (Jurkat cells) (1×106/ml), or were treated with 10ng/ml TNF-β, or 10ng/ml TNF-
β and 5μl/ml anti-TNF-β, or 10ng/ml TNF-α, or 10ng/ml TNF-α and 5μl/ml anti-TNF-α and
then co-cultured with T-lymphocytes for 8h. Additionally, in another set of experiments, pri-
mary human chondrocytes were either co-cultured with T-lymphocytes and/or with 5μM
resveratrol and/or 10ng/ml TNF-β and/or 10ng/ml TNF-α for 8h, or were transfected with Sir-
t1-ASO or Sirt1-SO in the presence of Lipofectin (10μl/ml) for 24h prior to co-treatment with
T-lymphocytes and 5μM resveratrol and 10ng/ml TNF-β or 10ng/ml TNF-α for 8h. After 8h
of co-culture, non-adherent T cells were carefully removed by gentle washing once with Hank
´s balanced salt solution (Biochrom, Germany) and photographed under a light microscope
(Zeiss, Jena, Germany). The number of adhered T-lymphocyte colonies on chondrocytes was
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determined by scoring 10 different microscopic fields. This experiment was repeated three
times independently and statistical analysis was done to obtain the final values.
Immunofluorescence analysis
The technique was performed as previously described in detail [42]. Briefly, primary human
chondrocytes were either left untreated or treated with 5μM resveratrol, or with 10ng/ml TNF-
β, or co-cultured with T-lymphocytes (1×106/ml) alone for 12h. Additionally, primary human
chondrocytes were co-cultured with T-lymphocytes and either treated with 10ng/ml TNF-β,
or with 5μM resveratrol, or with 10ng/ml TNF-β and 5μM resveratrol for 12h. Cells were
washed in Hanks’ solution (PBS) before methanol fixation and permeabilization of the cells for
10 min at ambient temperature (AT). This was followed by rinsing 3 times with a mixture of
protease-free bovine serum albumin (BSA) and PBS for 10min at AT and then incubated with
primary antibodies (Sirt1, NF-κB, 1:80 in PBS/BSA) in a humid chamber overnight at 4˚C.
Cultures were washed three times with PBS/BSA before incubation with rhodamine-red con-
jugated secondary antibody (diluted 1:80 in PBS/BSA) for 1.5h at AT and finally rinsed again
three times with PBS. Counter-staining was performed with 40,6-diamidino-2-phenylindole
(DAPI; Sigma-Aldrich Chemie) to visualize cell nuclei for 10 min. Cells were finally washed
once with aqua dest. and covered with fluoromount mountant (Sigma). Samples were evalu-
ated under a fluorescence microscope (Leica Microsystems, Wetzlar, Germany). Quantifica-
tion of positively stained cells was performed by scoring 100 cells from 10 different
microscopic fields.
Transmission electron microscopy (monolayer- and alginate cultures)
Serum-starved primary human chondrocytes were either left untreated, treated with various
concentrations of TNF-β (1, 5, 10 or 20ng/ml) for 1h, or co-treated with resveratrol 5μM and
various concentrations of TNF-β (0, 1, 5, 10 or 20ng/ml) for 1h in monolayer cultures. In a sec-
ond approach, monolayer cultured chondrocytes (1x106/ml) were transferred to alginate cul-
tures, treated as described above and cultured under similar conditions with serum-starved
medium for 10 days to examine the effects of TNF-β and/or resveratrol on chondrocytes differ-
entiation potential in a three-dimensional environment. Three-dimensional alginate cultures
were prepared as previously described [44, 45]. Briefly, the pellet of chondrocytes (1×106/ml)
was resuspended in alginate (2% in 0.15M NaCl, stirring for 1–2 h) and slowly added dropwise
into a solution containing 100mM CaCl2 at ambient temperature (AT). The alginate beads
polymerized in the presence of CaCl2 after 10 min. Subsequently, the CaCl2 solution was
removed and the alginate beads rinsed three times with 0.15M NaCl solution and twice with
serum-starved medium (3% FBS).The medium was changed every 3 days. The cultures were
grown in an incubator at 37˚C with 5% CO2 in air. These experiments were performed in trip-
licate, and the results are provided as mean values from three independent experiments. A
detailed description of the culture technique used for transmission electron microscopy has
been published [44, 45]. After fixation and post fixation in 1% tannic acid and 1% OsO4 solu-
tion, cells from monolayer or alginate cultures were rinsed and dehydrated in ascending
alcohol series. They were embedded in Epon, cut on a Reichert Ultracut (Leica, Wetzlar, Ger-
many) followed by contrasting with 2% uranyl acetate/lead citrate. For inspection a transmis-
sion electron microscope (EM 10 Zeiss, Institute of Pharmacology, Berlin, Germany) or a Jeol
1200 EXII, Akishima Tokyo, Japan (Department of Anatomy and Cell Biology, Martinsried,
Germany) was used.
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Quantification of apoptotic cell death
To quantify apoptosis and cells with mitochondrial changes, ultrathin sections of the samples
were prepared and evaluated with a transmission electron microscope. The number of cells
exhibiting typical morphological features of apoptotic cell death was determined by scoring
100 cells from 25 different microscopic fields per culture. The values were initially subjected to
one-way ANOVA and then later compared among groups using unpaired Student’s t-test, fol-
lowed by a post-hoc test to compare the parameters of each group.
MTT assay from alginate bead culture
To evaluate cell viability of chondrocytes in alginate bead culture, cells were retrieved from
alginate, as previously described in detail [44] and a MTT assay (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) was performed. Briefly, alginate beads were left untreated
or treated with various concentrations of TNF-β (0.1, 1, 5, 10 or 20ng/ml) or were co-stimu-
lated with resveratrol 5μM and various concentrations of TNF-β (0, 0.1, 1, 5, 10 or 20ng/ml)
for 14 days. To release the cells from the alginate, alginate beads were washed two times with
Hanks Salt Solution and dissolved in 55mM sodium citrate solution for 20–30 min. Subse-
quently, in triplicate, 100 μl of cell suspension was distributed to a 96-well-plate, to each well
were immediately added 10 μl MTT solution (5mg/ml) and the plate was incubated for 4h at
37˚C. Finally, 100μl of the MTT solubilisation solution (10% Triton x-100/acidic isopropanol)
was added per well, and the cells incubated overnight at 37˚C. Metabolically active cells were
evaluated through measuring the Optical Density at 550nm (OD550) using revelation 96-well
multiscanner plate ELISA reader (Bio-Rad Laboratories Inc. Munich, Germany). The results
obtained were calculated and were represented as percentage of survival relative to controls.
The experiments were repeated three times independently and statistical analysis was done to
obtain the final values.
Western blot analysis
Primary human chondrocytes in monolayer cultures were either left untreated or treated with
5μM resveratrol, or 10ng/ml TNF-β, or 5μM resveratrol and 10ng/ml TNF-β or co-cultured with
T-lymphocytes (1×106/ml) alone for 4h, or co-cultured with T-lymphocytes and additionally
treated with 10ng/ml TNF-β, or 5μM resveratrol or with 10ng/ml TNF-β and 5μM resveratrol
for 4h. In a second approach, serum-starved monolayer cultured primary human chondrocytes
were either left untreated or treated with 5μM resveratrol, or 10ng/ml TNF-β, or 10mM NAM,
or were co-treated with 5μM resveratrol and 10ng/ml TNF-β or 5μM resveratrol and 10mM
NAM for 4h. Additionally, chondrocytes were transfected with 0.5μM Sirt1-SO or Sirt1-ASO in
the presence of Lipofectin (10μl/ml) for 24h and either left untreated or co-treated with resvera-
trol (5μM) for 4h. In another set of experiments, serum-starved chondrocytes in alginate beads
were left untreated or treated with various concentrations of TNF-β (0.1, 1, 10ng/ml), or were
co-stimulated with 5μM resveratrol and various concentrations of TNF-β (0.1, 1, 10ng/ml) for 14
days. The whole-cell extracts were prepared for immunoblotting as previously described [25, 44,
46]. Whole cell lysate proteins were extracted from cultures on ice for 30 min. with lysis buffer
(50mM Tris-HCl, pH 7.2, 150mM NaCl, 1% (v/v) Triton X-100, 1mM sodium orthovanadate,
50mM sodium pyrophosphate, 100mM sodium fluoride, 0.01% (v/v) aprotinin, 4 mg/ml of pep-
statin A, 10mg/ml of leupeptin, 1mM phenyl methyl sulfonylfluoride, PMSF), total protein con-
centration was measured with the bicinchonic acid assay system (Uptima, Monlucon, France)
using bovine serum albumin as a standard, and Subsequently, samples were reduced with 2-mer-
captoethanol and equal quantities of protein (500ng/lane), separated under reducing condi-
tions by SDS-PAGE. After transfering onto nitrocellulose membranes using a transblot
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apparatus (Bio-Rad) and pre-incubation in blocking buffer (5% skimmed milk powder in
PBS, 0.1% Tween 20) for 2h, membranes were incubated with primary antibodies at 4˚C over-
night, washed three times with blocking buffer, and then further incubated with alkaline
phosphatase-conjugated secondary antibodies for 2h at AT. After further washing in 0.1M
Tris, pH 9.5, containing 0.05M MgCl2 and 0.1M NaCl, specific antigen-antibody complexes
were detected using nitro blue tetrazolium and 5-bromo-4-chloro-3-indoylphosphate (p-tolu-
idine salt; Pierce). Total protein amount was defined according to the bicinchoninic acid sys-
tem (Pierce, Rockford, IL, USA) using bovine serum albumin as a standard. Specific binding
was quantified by densitometry using ‘‘quantity one” (Bio-Rad Laboratories Inc. CA, USA).
Specific β-actin antibody was used for the internal control to normalize the sample amounts.
Statistical analysis
Experiments were performed three times as individual experiments with three replicates. For
statistical analysis, a Wilcoxon-Mann-Whitney test was applied. Score values for image quality
and presence of artifacts were compared for each sequence. A p value of<0.05 was considered
to establish statistically significant differences.
Results
The aim of the present study was to examine whether resveratrol could inhibit the inflamma-
tory role of TNF-β in an inflammatory microenvironment of primary human chondrocytes
and T-lymphocytes in vitro. To determine this, the mechanism by which resveratrol manifests
its effect was investigated against inflammatory pathways activated by TNF-β in chondrocytes
in monolayer and alginate cultures in vitro. The concentration of resveratrol or ethanol applied
in our study and the time of exposure had no suppressive effect on chondrocyte cell viability.
Knock-down of Sirt1 modulates resveratrol-induced inhibition of TNF-β-
or TNF-α-mediated adhesiveness of T-lymphocytes to chondrocytes in
vitro
It has been shown that inflammation in RA is mediated also through recruitment of lympho-
cytes to the site of inflammation [47] and our group could previously demonstrate that TNF-β
treatment of chondrocytes with increased dosages of TNF-β resulted in an almost 2fold
increase in the adherence of T-lymphocytes [14], highlighting a novel role for TNF-β in sup-
porting an inflammatory milieu and stimulating ongoing inflammation in chondrocytes. To
investigate further the role of TNF-β signaling in attracting T-lymphocytes and inducing an
inflammatory microenvironment, we performed an adhesion assay of chondrocytes with T-
lymphocytes. Serum starved chondrocytes were grown to sub-confluence in monolayer culture
(Fig 1) and either cultured alone or co-cultured with T-lymphocytes or co-cultured with T-
lymphocytes and treated as described in Material and Methods. Stimulation of co-cultures
with TNF-β or TNF-α resulted in 2 to 2.5 fold increase in the adherence of T-lymphocytes to
chondrocytes compared to control, underlining the role of these cytokines in stimulating and
supporting an inflammatory microenvironment (Fig 1B, 1C, 1J and 1K). In contrast to this,
treatment of co-cultures with TNF-β and anti-TNF-β similar to TNF-α and anti-TNF-α, or
resveratrol with either TNF-β or TNF-α markedly suppressed T-lymphocyte adherence to
chondrocytes (Fig 1D, 1E, 1L and 1M). As resveratrol has been reported to be a specific potent
activator of histone deacetylase Sirt1 [48], we additionally investigated whether resveratrol-
suppression of TNF-β-induced inflammatory adherence of T-lymphocytes to chondrocytes is
mediated via a Sirt1 dependent pathway. Prior to co-culture with T-lymphocytes and co-
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treatment with resveratrol, TNF-β or TNF-α, chondrocytes were transfected with Sirt1-ASO
or Sirt1-SO, as described in Materials and Methods (Fig 1F, 1G, 1N and 1O). In TNF-β- or
TNF-α-stimulated co-cultures transfected with control Sirt1-SO, T-lymphocyte adherence to
chondrocytes was suppressed by resveratrol treatment. In contrast, knockdown of Sirt1 with
ASO against Sirt1 clearly increased TNF-β- or TNF-α-induced adherence of T-lymphocytes in
spite of resveratrol treatment. These results indicate clearly that resveratrol-induced suppres-
sion of inflammatory microenvironment in chondrocytes by TNF-β is mediated, at least in
part via activation of a Sirt1 dependent pathway. Statistical evaluation of the Jurkat cell colo-
nies adherent to chondrocytes was estimated and quantified by counting 100 colonies from 25
microscopic fields. As shown in Fig 1H and 1P, this confirmed the results from Fig 1A–1G
and 1I–1O.
TNF-β- similar to T-lymphocytes-induced NF-κB-signalling in
chondrocytes is suppressed by resveratrol-activated Sirt1 up-regulation
To examine whether the observed enhanced adhesiveness of T-lymphocytes to chondrocytes
by TNF-β or T-lymphocytes is correlated/associated with up-regulation of inflammatory sig-
nalling in chondrocytes, we performed immunocytochemical analysis for phosphorylated-NF-
κB (Fig 2). It has been reported that translocation of NF-κB to the nucleus is necessary for the
Fig 1. Effects of resveratrol and ASO against Sirt1 or TNF-β- or to TNF-α-mediated adhesiveness of T-
lymphocytes to chondrocytes. Serum-starved human primary chondrocytes (PCH) were cultured to sub-
confluence in monolayer culture and were either left untreated or co-cultured with T-lymphocytes and treated
with TNF-β (a-g) or TNF-α (i-o) as described in Material and Methods. After being washed with phosphate-
buffered saline, adhesion of T-lymphocytes (arrows) to chondrocytes was evaluated by light microscopy.
Original magnification, x400; bar, 30nm. The number of adhered colonies of T-lymphocytes to chondrocytes
was estimated and quantified by counting 10 microscopic fields per culture (h and p).
https://doi.org/10.1371/journal.pone.0186993.g001
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regulation of gene expression by NF-κB and the translocation of activated NF-κB is preceded
by phosphorylation of the p65 subunit of NF-κB [49, 50]. Serum starved chondrocytes were
cultured on glass plates in monolayer and were either left untreated, treated with resveratrol,
TNF-β or co-cultured with T-lymphocytes and treated as described in Material and Methods.
In untreated chondrocytes or treated with resveratrol, inactivated NF-κB was mainly found in
the cytoplasm (Fig 2A and 2B). In contrast, treatment with TNF-β alone, co-culture with T-
lymphocytes or co-culture with T-lymphocytes and TNF-β markedly induced NF-κB activa-
tion in chondrocytes through enhanced nuclear translocation of p65 (Fig 2C–2E). Treatment
with resveratrol alone (Fig 2B), or co-treatment with TNF-β (not shown) or in combination
with T-lymphocytes alone (Fig 2F) or T-lymphocytes in combination with TNF-β (Fig 2G)
strongly suppressed NF-κB activation as shown by significantly fewer NF-κB-nuclear positive
stained cells. These results indicate that resveratrol-induced suppression of TNF-β- similar to
T-lymphocytes-enhanced inflammatory signaling in chondrocytes is mediated also through
inhibition of NF-κB activation. Quantification of NF-κB-nuclear positively stained cells con-
firmed the immunofluorescence results (Fig 2H).
We could previously show that there is a causal relationship between Sirt1 and NF-κB sig-
naling pathway during chondrogenesis [25]. Therefore, next we examined whether the
observed suppression of NF-κB inflammatory pathway by resveratrol in chondrocytes by
TNF-β and/or T-lymphocyte is mediated via Sirt1 activation. Serum starved chondrocytes
were treated as described above and submitted to immunofluorescent labelling with anti-Sirt1
(Fig 3). The immunofluorescence analysis revealed that treatment of chondrocytes with TNF-
β or co-culture with T-lymphocytes or co-culture with T-lymphocytes and TNF-β strongly
suppressed Sirt1 nuclear localization compared to control (Fig 3C–3E). In contrast to this,
treatment with resveratrol alone (Fig 3B) or in combination with T-lymphocytes alone or with
T-lymphocytes in combination with TNF-β (Fig 3F and 3G) significantly upregulated Sirt1
nuclear localization as confirmed by quantification of positively stained cells (Fig 3H). Taken
together, these findings indicate that resveratrol-activated Sirt1 suppressed inflammatory-
induced signaling by TNF-β similar to T-lymphocytes in chondrocytes, highlighting the cru-
cial role of Sirt1 in inhibiting TNF-β-induced inflammatory environment by the NF-κB
pathway.
Resveratrol suppresses TNF-β-induced degradation and apoptosis in
chondrocytes in monolayer and alginate cultures
For up-keeping of chondrogenic potential, cell-cell and cell-matrix interaction between chon-
drocytes and their surrounding matrix are essential [51]. Therefore, to examine whether the
observed TNF-β-induced inflammatory signaling pathways in chondrocytes are associated
with degenerative cell morphology changes and loss of cell-cell and cell-matrix interaction,
ultrastructural electron microscopic investigations in monolayer and 3-D microenvironment
alginate culture were performed (Figs 4 and 5). For monolayer investigations, chondrocytes
were either left untreated or treated with various concentrations of TNF-β as described in
Material and Methods. Untreated or resveratrol treated chondrocytes in monolayer cultures
showed typical fibroblast-like shape with small cytoplasmic processes, a large, mostly euchro-
matic nucleus with nucleoli and a well-structured cytoplasm (Fig 4A and 4F). Treatment with
TNF-β revealed substantial degenerative changes in chondrocytes morphology, typical micro-
villi-like processes disappeared, cell shapes became rounded, multiple vacuoles appeared as
well as swollen and degenerated cell organelles (especially mitochondria, rough ER) and cell
nuclei containing more condensed heterochromatin could be observed. A clear dose-depen-
dent increase of TNF-β-induced morphological signs of degeneration and degradation in
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chondrocytes was observed. The dosage of 20ng/ml TNF-β caused almost completely cell deg-
radation and apoptosis (Fig 4B–4E). In contrast to this, co-treatment with resveratrol, resulted
in cells with fewer apoptotic features in cultures treated with up to 10ng/ml TNF-β, demon-
strating a resveratrol-induced protective effect against TNF-β-induced cellular degeneration
and apoptosis in chondrocytes (Fig 4G–4J). To confirm the morphological findings and
Fig 2. Immunohistochemical analysis of p65 localization after treatment with TNF-β and/or T-
lymphocytes and/or resveratrol as revealed by immunofluorescence microscopy in chondrocytes.
A-G: NF-κB-p65 localization in human chondrocytes after treatment with resveratrol, TNF-β and/or co-culture
with T-lymphocytes as described in Material and Methods. For immunolabeling, cells were incubated with
primary antibodies against NF-κB-p65, followed by incubation with rhodamine-coupled secondary antibodies
and counterstaining with DAPI to visualize cell nuclei. Original magnification, x400; bar, 30nm. To quantify the
chondrocytes with nuclear-positive translocation p65 (H), the labeled cultures were examined by counting 100
cells from 10 microscopic fields. The results are provided as the mean values with S.D. from three
independent experiments. Values were compared with the control, and statistically significant values with
p<0.05 are designated by (*), and p<0.01 is designated by (**).
https://doi.org/10.1371/journal.pone.0186993.g002
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quantify them, cells displaying severe mitochondrial changes or apoptosis were counted
among 100 cells from 25 microscopic fields (Fig 4k). In monolayer culture, TNF-β effectively
induced apoptosis in a dose-dependent manner with 38% apoptotic cells at 10ng/ml, 28% at
5ng/ml, 21% at 1ng/ml compared to 13% in untreated or 12% in resveratrol treated chondro-
cytes. Apoptosis in resveratrol and TNF-β co-treated cultures was significantly lower with 18%
at 10ng/ml, 18% at 5ng/ml and 13% at 1ng/ml TNF-β. Dose of 20ng/ml TNF-β alone or in
Fig 3. Effect of resveratrol and/or TNF-β and/or T-lymphocytes on the expression of Sirt1 revealed by
immunofluorescence in chondrocytes. A-G: Sirt1 expression in human chondrocytes after treatment with
resveratrol, TNF-β and/or co-culture with T-lymphocytes as described in Material and Methods. Immunolabeling
was performed with primary antibodies against Sirt1, followed by incubation with rhodamine-coupled secondary
antibodies and counterstaining with DAPI to visualize cell nuclei. Original magnification, x400; bar, 30nm.
Quantification of cells with positive nuclear labeling (H) was examined by counting 100 cells from 10 microscopic
fields. The results are provided as the mean values with S.D. from three independent experiments. Values were
compared with the control, and statistically significant values with p<0.05 are designated by (*), and p<0.01 is
designated by (**).
https://doi.org/10.1371/journal.pone.0186993.g003
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combination with resveratrol was highly toxic in monolayer culture, with 76% of apoptotic
cells at 20ng/ml and 72% in co-treated cultures (Fig 4k).
For investigations in 3-D microenvironment alginate culture, alginate beads were left
untreated or treated with 5μM resveratrol and/or with various concentrations of TNF-β, as
described in Material and Methods (Fig 5). Untreated or resveratrol treated cultures exhibited
viable cells with well-developed cell organelles, organized in well-developed cartilage nodules
and embedded in an extensive, fine fibrillar matrix tightly attached to the cytoplasmic mem-
brane. (Fig 5A and 5F). Treatment with TNF-β, lead to dose-dependent increase in morpho-
logical signs of degeneration and degradation of chondrocytes such as multiple vacuoles,
swelling, degeneration of cell organelles, nuclear fragmentation, formation of apoptotic bodies
and detachment between chondrocytes and extracellular matrix (Fig 5B–5E). In contrast, co-
Fig 4. Electron microscopic evaluation on cellular degeneration and apoptosis in chondrocytes in
monolayer cultures after treatment with resveratrol and/or TNF-β. A-J: Serum-starved human primary
chondrocytes (Ch) were cultured to sub-confluence in monolayer culture and were either left untreated or
treated with different concentration of TNF-β (1, 5, 10 and 20ng/ml) and/or co-treated with resveratrol and
evaluated with a transmission electron microscope. Untreated control (Co.), chondrocytes containing
mitochondria, rough endoplasmic reticulum and many other cell organelles (A). In contrast, treatment of
chondrocytes with TNF-β resulted in degenerative changes of the cells. Cells became rounded and the
nucleus contained more condensed chromatin, multiple vacuoles, swelling of rough endoplasmic reticulum,
and clustering of swollen mitochondria was visible. Higher concentration of TNF-β (10, 20ng/ml) led to the
formation of apoptotic bodies and cell lysis (arrows). A-J: x5000; bar = 1μM. k: To quantify cellular degradation
and apoptosis in chondrocytes monolayer cultures, 100 cells from 25 microscopic fields were counted and
results presented are mean values with standard deviations from three independent experiments. Values
were compared with the control and statistically significant values with p<0.05 were designated by (*) and
p<0.01 were designated by (**).
https://doi.org/10.1371/journal.pone.0186993.g004
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treatment with resveratrol protected the chondrocytes from TNF-β-induced cellular degenera-
tion and apoptosis at concentrations from 1 to 10ng/ml, but not at higher concentration of
20ng/ml (Fig 5G–5J). Statistical evaluation of the ultrastructural data of chondrocytes in algi-
nate microenvironment culture displaying severe apoptosis was performed by counting 100
cells from 25 microscopic fields. As shown in Fig 5K TNF-β, effectively induced cell death in
3D microenvironment alginate culture in a dose-dependent manner with 51% apoptotic cells
at 10ng/ml, 38% at 5ng/ml, 27% at 1ng/ml compared to 18% in untreated or 16% in resveratrol
treated chondrocytes. Apoptosis in resveratrol and TNF-β co-treated cultures was significantly
lower with 35% at 10ng/ml, 29% at 5ng/ml and 19% at 1ng/ml TNF-β. Dose of 20ng/ml TNF-β
alone or in combination with resveratrol was evidently toxic, with 88% of apoptotic cells at 20
ng/ml and 83% in co-treated cultures (Fig 5K). Taken together, chondrocytes treated with
20ng/ml TNF-β, as opposed to controls or with resveratrol treated cells, were not able to sur-
vive in alginate cultures and they underwent cell death.
Fig 5. Effect of resveratrol on TNF-β-induced cellular degeneration and apoptosis in chondrocytes in
3-D alginate cultures. A-J: Serum-starved human primary chondrocytes (Ch) were cultured in alginate
beads (*) and were either left untreated (Co.) or were treated with different concentrations of TNF-β (1, 5, 10
and 20ng/ml) or resveratrol (5μM) or a combination of resveratrol (5μM) and TNF-β (1, 5, 10 and 20ng/ml) for
14 days. Magnification: x5000, bar = 1μM. k: morphological features of apoptotic cell death (arrows) were
quantified by counting 100 in cells from 25 different microscopic fields and results presented are mean values
with standard deviations from three independent experiments. Significant values were compared with the
control and statistically significant values with p<0.05 were designated by (*) and p<0.01 were designated by
(**).
https://doi.org/10.1371/journal.pone.0186993.g005
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Resveratrol suppresses TNF-β-induced inhibition of chondrocyte
viability and proliferation in alginate culture
To evaluate cell viability in response to resveratrol and TNF-β treatment, chondrocytes in algi-
nate bead culture were retrieved from alginate and a MTT assay was performed. Alginate beads
were left untreated or treated with 5μM resveratrol and/or with various concentrations of TNF-
β, as described in detail in Material and Methods. As shown in Fig 6 treatment with lowest con-
centration of 0.1ng/ml TNF-β had little effect on cell viability compared to untreated cells. In
contrast, a significant dose-dependent decrease of 22%, 44%, 60% and 84% in cell viability of
chondrocytes treated with 1, 5, 10, and 20ng/ml TNF-β respectively was observed. Cell viability
in cells treated with resveratrol alone or combination of resveratrol and 0.1ng/ml TNF-β was
similar to untreated cells. Interestingly, it was noted that co-treatment with resveratrol markedly
suppressed decrease of 11%, 27%, 44% and 77% in cell viability of chondrocytes treated with 1,
5, 10 and 20 ng/ml TNF-β respectively compared to TNF-β mono-treatment.
Resveratrol suppresses TNF-β- or T-lymphocytes-induced down-
regulation of extracellular matrix, Ki67, Sirt1 and Sox9 in chondrocytes
Serum starved chondrocytes were cultured in monolayer and either left untreated or treated
with resveratrol, or TNF-β, or co-treated with resveratrol and TNF-β, or co-cultured with T-
lymphocytes alone or additionally with TNF-β with or without resveratrol as described in
Material and Methods. Western blot analysis was performed by probing whole cell lysates with
antibodies against collagen type II, Ki67, Sirt1, the cartilage-specific transcription factor Sox9
and β-actin (Fig 7). As shown in Fig 7, chondrocytes stimulated with TNF-β alone or co-cul-
tured with T-lymphocytes and/or TNF-β showed a significant down-regulation of synthesis of
collagen type II, Ki67, Sirt1 and Sox9 expression (Fig 7). In contrast, treatment of chondrocytes
with resveratrol followed by stimulation with TNF-β, or co-cultured with T-lymphocytes and/
or TNF-β with resveratrol, resulted in a significant inhibition of cytokine-induced effects on
the above mentioned protein expression (Fig 7). Interestingly, treatment of the chondrocytes
with TNF-β alone or co-culture with T-lymphocytes down-regulated the expression of the
above-mentioned proteins in the same manner in chondrocytes and co-culture of the chon-
drocytes with T-lymphocytes and treatment with TNF-β decreased the levels of the above
Fig 6. Effects of resveratrol and/or TNF-β on the proliferation of chondrocytes in 3-D alginate culture.
Serum-starved human articular chondrocytes were either left untreated or treated with different concentrations of
TNF-β alone (0.1, 1, 5, 10, 20ng/ml) or were treated with resveratrol (5 μM) followed by treatment with different
concentrations of TNF-β (0, 0.1, 1, 5, 10, 20ng/ml) for 14 days. Cell viability was examined by MTT assay. The
MTT assay is a spectrophotometric measurement of the cell viability as a function of the mitochondrial activity.
The results are provided as mean values with standard deviations from at least three independent experiments.
Values were compared to the control and statistically-significant values with p<0.05 are designated by (*) and
p<0.01 designated by (**).
https://doi.org/10.1371/journal.pone.0186993.g006
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mentioned-proteins more than each agent by itself (Fig 7). Taken together, these results dem-
onstrate that resveratrol inhibited TNF-β-induced down-regulation of extracellular matrix
(ECM) production, chondrocytes proliferation and cartilage-specific transcription factor also
in an inflammatory microenvironment with T-lymphocytes, underlining the prophylactic
potential of resveratrol to protect the chondrogenic potential in chondrocytes.
Resveratrol suppresses TNF-β- or T-lymphocytes-induced NF-κB-
dependent Pro-inflammatory, matrix-degrading and apoptotic gene
products in chondrocytes
We examined further, whether resveratrol can modulate the expression of TNF-β- and/or T-
lymphocytes-induced NF-κB-regulated gene products involved in the inflammatory and deg-
radative processes in chondrocytes. Serum starved chondrocytes were left untreated or treated
Fig 7. Resveratrol blocks TNF-β- or T-lymphocytes-induced down-regulation of extracellular matrix,
Ki67, Sirt1, Sox9, expression of NF-κB and NF-κB-dependent pro-inflammatory, matrix-degrading and
apoptotic gene products in chondrocytes. Serum starved chondrocytes were cultured in monolayer and
either left untreated or treated with resveratrol, or TNF-β, or co-treated with resveratrol and TNF-β, or co-
cultured with T-lymphocytes alone or additionally with TNF-βwith or without resveratrol. Whole-cell extracts
were prepared and then analyzed by western blotting with indicated antibodies. Densitometric evaluation of
protein expression as revealed by western blot analysis was performed in triplicate. Bars represent the mean
values for collagen type II, Ki67, Sirt1, Sox9, MMP-9, MMP-13, COX-2, cleaved caspase-3 and p-NF-κB.
Housekeeping protein β-actin served as a loading control in all experiments. The results are provided as
mean values with standard deviations from at least three independent experiments. Values were compared to
the control and statistically-significant values with p<0.05 are designated by (*) and p<0.01 designated by
(**).
https://doi.org/10.1371/journal.pone.0186993.g007
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with resveratrol alone and/or with TNF-β, and/or co-cultured with T-lymphocytes as
described in Materials and Methods. Equal amounts of total proteins were separated by
SDS-PAGE and analyzed by immunoblotting using antibodies raised against MMP-9/-13,
COX-2, activated caspase-3 and phosphospecific-p65 as well as β-actin. Fig 7 demonstrates a
significant up-regulation of synthesis of MMP-9/-13, cleavage of caspase-3 and phosphoryla-
tion of NF-κB in chondrocytes treated with TNF-β and/or co-cultured with T-lymphocytes,
compared with basal control (Fig 7). To date, TNF-β induced in a similar way to T-lympho-
cytes the expression of the above-mentioned proteins in the same manner in chondrocytes
and co-culture of the chondrocytes with T-lymphocytes and treatment with TNF-β signifi-
cantly increased the levels of the above mentioned-proteins more than each agent by itself.
Treatment with resveratrol suppressed the expression of the mentioned proteins in all combi-
nations (Fig 7). Taken together, these results further strengthen the role of resveratrol-depen-
dent signaling in modulating TNF-β-induced NF-κB-regulated inflammation in chondrocytes
in T-lymphocytes microenvironment.
Resveratrol suppresses down-regulation of extracellular matrix, Ki67,
Sirt1 and Sox9 in chondrocytes induced by TNF-β or NAM but not by
ASO against Sirt1
As shown above, resveratrol/Sirt1-dependently blocked TNF-β- and/or T-lymphocytes-
induced inflammation and degenerative changes in PCH. To investigate further the role of
Sirt1 in TNF-β-induced degradative and degenerative changes in chondrocytes in an inflam-
matory microenvironment, chondrocytes were either left untreated or treated with resveratrol,
TNF-β, NAM and/or transfected with Sirt1-ASO or–SO as described in Materials and Meth-
ods. Equal amounts of total proteins were separated by SDS-PAGE and analyzed by immuno-
blotting using antibodies raised against collagen type II, Ki67, Sirt1, Sox9 and β-actin. As
shown in Fig 8, there was a significant down-regulation of synthesis of collagen type II, Ki67,
Sirt1 and Sox9 expression in chondrocytes treated with TNF-β or NAM and ASO against
Sirt1, compared with basal control, resveratrol and Sirt1-SO treatment. In contrast, co-treat-
ment with resveratrol up-regulated the above mentioned protein expression to control levels
in all treatment groups, except in cells treated with Sirt1-ASO (Fig 8). These results demon-
strate an essential role for Sirt1 in TNF-β-mediated inflammatory effects in cartilage and
underline the prophylactic potential of resveratrol as natural Sirt1-activator to protect the
chondrogenic potential in chondrocytes.
Resveratrol suppresses up-regulation of NF-κB-dependent pro-
inflammatory, matrix-degrading and apoptotic gene products in
chondrocytes induced by TNF-β- or NAM but not by ASO against Sirt1
Next, we examined further the role of Sirt1 on TNF-β-induced inflammatory pathways in
PCH. Equal amounts of total proteins were separated by SDS-PAGE and analyzed by immu-
noblotting using antibodies raised against MMP-9/-13, COX-2 and activated caspase-3 as well
as β-actin. As shown in Fig 8, a significant up-regulation of synthesis of MMP-9/-13, cleavage
of caspase-3 and phosphorylation of NF-κB in chondrocytes treated with TNF-β or NAM and
ASO against Sirt1, compared with basal control, resveratrol and Sirt1-SO treatment. In con-
trast, co-treatment with resveratrol down-regulated the above mentioned protein expression
to control levels in all treatment groups, except in cells treated with Sirt1-ASO (Fig 8). Taken
together, these findings suggest that inhibition of Sirt1 on the protein level by Sirt1 inhibitor
NAM and on the mRNA level by ASO equally produces an inflammatory response as by
stimulation with pro-inflammatory cytokine TNF-β and that resveratrol can suppress this
Resveratrol inhibits lymphotoxin α (TNF-β)-induced inflammation in chondrocytes
PLOS ONE | https://doi.org/10.1371/journal.pone.0186993 November 2, 2017 16 / 26
inflammation signaling through activation of Sirt1, if inhibition of Sirt1 is induced at the pro-
tein level and not at the gene level.
Resveratrol modulates TNF-β-induced inflammation and apoptosis in
human chondrocytes in 3-D alginate cultures in vitro
Several studies suggest that in alginate culture only cells with chondrogenic potential can sur-
vive and alginate functions as a selective filter station separating vital from nonvital chondro-
cytes. The alginate environment appears to be an ideal model for the study of chondrocyte
differentiation and matrix components in a three-dimensional system [45, 52].
To examine, whether resveratrol blocks the TNF-β-induced inhibition of extracellular
matrix, Ki67, Sirt1, Sox9 and up-regulation of NF-κB-dependent inflammatory pathways and
apoptosis, serum-starved chondrocytes in alginate beads were left untreated or treated with
Fig 8. Effects of resveratrol, TNF-β, NAM, ASO against Sirt-1 on extracellular matrix, Ki67, Sirt1, Sox9,
NF-κB, NF-κB-dependent pro-inflammatory, matrix-degrading and apoptotic gene products in
chondrocytes. Serum starved chondrocytes in monolayer culture were either left untreated or treated with
resveratrol (5μM), TNF-β (10ng/ml), or with Sirt1-SO or -ASO (0.5μM) in the presence of Lipofectin for 24h, or
NAM (10mM), or cells were pretreated with resveratrol (5μM) for 1h followed by co-treatment with TNF-β
(10ng/ml), Sirt1-SO, or -ASO (0.5μM) in the presence of Lipofectin for 24h, NAM (10mM) as described in
Material and Methods. Whole cell extracts were prepared, separated by SDS-PAGE, and subjected to western
blot analysis using relevant antibodies. Densitometric evaluation of protein expression as revealed by western
blot analysis was performed in triplicate. Bars represent the mean values for collagen type II, Ki67, Sirt1, Sox9,
MMP-9, MMP-13, COX-2, cleaved caspase-3 and p-NF-κB. Housekeeping protein β-actin served as a loading
control in all experiments. The results are provided as mean values with standard deviations from at least three
independent experiments. Values were compared to the control and statistically-significant values with p<0.05
are designated by (*) and p<0.01 designated by (**).
https://doi.org/10.1371/journal.pone.0186993.g008
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various concentrations of TNF-β or were co-stimulated with resveratrol and various concen-
trations of TNF-β for 14 days as described in Material and Methods.
A: Resveratrol suppresses down-regulation of extracellular matrix, Ki67, Sirt1 and Sox9
in chondrocytes induced by TNF-β in 3-D alginate culture. Chondrocytes in 3-D alginate
microenvironment stimulated with TNF-β alone showed a significant down-regulation of syn-
thesis of collagen type II, Ki67, Sirt1 and Sox9 in a dose-dependent manner, compared with
basal control and resveratrol (Fig 9). At a concentration of 10ng/ml the mentioned proteins
were almost completely inhibited. In contrast, co-treatment with resveratrol up-regulated the
above mentioned protein expressions to control levels in all TNF-β-treated groups, expect in
cells treated with 10ng/ml TNF-β and this was concentration dependent (Fig 9).
B: Resveratrol suppresses up-regulation of NF-κB-dependent pro-inflammatory,
matrix-degrading and apoptotic gene products in chondrocytes induced by TNF-β in 3-D
alginate culture. Whole cell lysates were fractionated and analyzed by immunoblotting using
anti-MMP-9/-13, anti-COX-2 and anti-activated caspase-3 as well as β-actin. As shown in Fig 9,
in western blot analysis, treatment with TNF-β clearly up-regulated the expression of the men-
tioned proteins in a dose-dependent manner. In contrast, co-treatment with resveratrol
Fig 9. Effects of resveratrol on TNF-β-induced inflammation and apoptosis in chondrocytes in 3D-
alginate cultures. Serum-starved chondrocytes in alginate beads were left untreated or treated with various
concentrations of TNF-β or were co-stimulated with resveratrol and various concentrations of TNF-β for 14
days as described in Material and Methods. Whole cell lysates were fractionated and subjected to western
blotting with indicated antibodies. Densitometric evaluation of protein expression as revealed by western blot
analysis was performed in triplicate. Bars represent the mean values for collagen type II, Ki67, Sirt1, Sox9,
MMP-9, MMP-13, COX-2, cleaved caspase-3 and p-NF-κB. Housekeeping protein β-actin served as a
loading control in all experiments. The results are provided as mean values with standard deviations from at
least three independent experiments. Values were compared to the control and statistically-significant values
with p<0.05 are designated by (*) and p<0.01 designated by (**).
https://doi.org/10.1371/journal.pone.0186993.g009
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significantly decreased the expression of the mentioned proteins in a concentration-dependent
manner to levels similar to control cultures (Fig 9). Taken together, these results further con-
firmed the role of resveratrol-dependent signaling in modulating TNF-β-induced NF-κB-regu-
lated gene products, and further suggest that TNF-β is one of the major cytokines mediating
inflammations in RA/OA microenvironment.
Discussion
The goal of this study was to examine the inflammatory role of lymphotoxin α (TNF-β) in an
inflammatory microenvironment of primary human chondrocytes and T-lymphocytes in vitro
and to determine the anti-inflammatory potential of resveratrol signaling to suppress inflam-
matory pathways activated by TNF-β in chondrocytes in monolayer and 3D alginate cultures.
We have made the following novel findings: (I) TNF-β-mediated adhesiveness of T-lympho-
cytes to chondrocytes could be significantly reduced by resveratrol and this effect could be inhib-
ited by knock-down of Sirt1 with ASO, (II) resveratrol suppressed NF-κB activation induced by
TNF-β or T-lymphocytes in chondrocytes, (III) resveratrol also down-regulated NF-κB depen-
dent gene products involved in cell proliferation (e.g. Ki67), inflammatory (COX-2), in matrix
degrading (MMP-9/-13) and apoptotic (cleaved caspase-3) signaling pathways induced by TNF-
β- or T-lymphocytes in the same manner, (IV) this downregulation led to the suppression of
apoptosis induced by cytokines and T-lymphocytes, (V) Finally, we showed for the first time,
that TNF-β- similar to T-lymphocytes-mediated inflammation was inhibited by resveratrol in a
Sirt1-dependent manner, highlighting the crucial role of this enzyme in regulation of TNF-β-
induced inflammation signaling in chondrocytes.
Rheumatoid arthritis (RA) is an inflammatory joint disease affecting 0.5–1% of adults,
with 5–50 per 100 000 new cases annually [2]. Indeed, recruitment of lymphocytes to the
site of inflammation plays a pivotal role in mediating inflammation in RA [47]. It is well
characterized that overproduction and overexpression of TNF-α acts as a key initiator in
the inflammatory cascade, activating members of the Interleukin-family such as Interle-
kuin-1β (IL-1β), enhancing interactions between T-and B-lymphocytes, synovial-like fibro-
blasts and macrophages, leading to synovial inflammation and joint destruction [3, 53].
However, not all adverse effects in RA can be related to TNF-α signaling, as approximately
in 30% of patients treatment with biologic therapy (typically initiated with TNF-α blockers)
fails, placing them at risk of further cartilage and joint damage [54]. Importantly, this indi-
cates the participation of other cytokines in the early pathogenesis of RA. Interestingly, an
increasing body of evidence suggested that the TNF-α homologue Lymphotoxin α, alias
TNF-β, plays a pivotal role in inflammatory joint environment [8, 12, 13]. Indeed, a recent
report from our laboratory revealed that in an in vitro model of inflammatory joint environ-
ment TNF-β enhanced inflammation in chondrocytes, similar to IL-1β [14].
We showed in this study for the first time that TNF-β, similar to TNF-α enhances recruit-
ment and adherence of T-lymphocytes to chondrocytes, underling the potential of TNF-β in
stimulating and supporting an inflammatory microenvironment in chondrocytes. Indeed, it
has been previously shown that an allelic variant in the TNF-β gene leads to higher TNF-β
response in mononuclear cells after stimulation with mitogens [55]. The authors assumed that
these allelically varying TNF-β responses of activated T-lymphocytes might contribute to the
slow and self-protruding inflammatory mechanisms of local autoimmune reactions and this
might be relevant for MHC-associated predispositions for autoimmune diseases [55]. Interest-
ingly, recently Shaker et al. have further shown that polymorphisms in the TNF-β gene
increase susceptibility to RA [56].
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Additionally, in this study, we evaluated for the first time that co-treatment with the natural
polyphenol resveratrol suppressed T-lymphocytes adherence to chondrocytes in TNF-β as well
as in T-lymphocytes treated cultures and this effect of resveratrol was inhibited by knock-
down of Sirt1 with antisense oligonucleotides (Sirt1-ASO). This demonstrates that inflamma-
tion in chondrocytes by TNF-β is indeed mediated similar to inflammation by T-lymphocytes.
Further, this indicates clearly, that resveratrol-induced suppression of inflammatory microen-
vironment by TNF-β or T-lymphocytes in chondrocytes is, at least in part, dependent on acti-
vation of Sirt1 pathway. These results are consistent with those from previous studies that
showed that the multi-targeted, natural polyphenol compound resveratrol has been linked
with anti-inflammatory and chondroprotective properties in chondrocytes [21–23] and fur-
ther has been shown to significantly up-regulate the NAD+-dependent Histondeacetylase
Sirt1 in normal and osteoarthritic chondrocytes [24, 25]. Furthermore, it has been well studied,
that activation of Sirt1 plays a pivotal role in chondrocytes differentiation and encourages sur-
vival under stress conditions [25, 29]. Moreover, this could explain why TNF-α induced
inflammation leads to Sirt1 overexpression in synovial tissue of RA patients [27].
To determine the mechanisms by which the pro-inflammatory signaling of TNF-β in
enhancing adhesiveness of T-lymphocytes to chondrocytes and the activation of inflammation
cascade in chondrocytes is regulated, we next investigated with immunofluorescence, how
TNF-β-modulated activation of NF-κB and Sirt1 in comparison to T-lymphocytes effects.
Indeed, it has been shown in chondrocytes that activated NF-κB is involved in regulation of
adhesion, cell-cycle, apoptosis, survival and inflammatory processes by activating IL-1β, TNF-
α, IL-6, Cox-2 and MMPs [10, 11, 57, 58]. For activation of NF-κB dependent pro-inflamma-
tory signaling cascade, following phosphorylation and ubiquitination, the p65 and p50 sub-
units dissociate from the IκBα complex and translocate to the nucleus to bind to NF-κB
recognition sites in the promoter regions [50]. Further, it has been already reported that TNF-
β possesses similar but less potent inflammatory potential than TNF-α [59]. Interestingly, in a
recent report, we could show that TNF-β induced activation of NF-κB similar to IL-1β in pri-
mary human chondrocytes [14]. In this report, we found now for the first time that indeed,
TNF-β, similar to T-lymphocytes, induced activation and nuclear translocation of NF-κB and
concomitantly suppressed Sirt1 activation. Furthermore, we could show that resveratrol co-
treatment with either TNF-β or T-lymphocytes significantly up-regulated Sirt1 and concomi-
tantly blocked NF-κB activation and nuclear translocation in chondrocytes. In fact, several
lines of evidence have shown that resveratrol is a suppressor of the NF-κB transcription factor
[60, 61] and a potent activator of Sirt1 in chondrocytes [24, 48]. These results highlight the cru-
cial role of Sirt1 in inhibiting T-lymphocytes- or TNF-β-induced pro-inflammatory microen-
vironment by the NF-κB pathway in chondrocytes.
We have previously shown that untreated primary chondrocytes have very low TNF-β
expression and that stimulation with a pro-inflammatory cytokine like IL-1β induced TNF-β
in chondrocytes [14]. However, the molecular mechanism(s) of TNF-β on chondrogenic
potential, cell viability, chondrocytes morphology, cell-cell contacts or cell-matrix interactions
of chondrocytes has not been explored. Here, we now demonstrate with ultrastructural investi-
gations and MTT-assay that indeed, up-regulation of inflammatory signaling pathways by
TNF-β are associated with reduced cell viability, degenerative cell morphology changes, loss of
cell-cell and cell-matrix interaction and finally resulting in apoptosis. Interestingly, these mor-
phological alterations are similar to those described for degenerative and inflammatory activa-
tion in chondrocytes by TNF-α and IL-1β [22, 58, 62]. We further showed that resveratrol
treatment protected the cells from TNF-β-induced degradative and apoptotic morphological
alterations up to certain concentrations of TNF-β. These results are in accordance with results
from previous studies from our laboratory and others underling the potential of resveratrol to
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suppress pro-inflammatory signaling in chondrocytes and exhibit a chondroprotective effect
[21, 23, 37].
To examine the underlying downstream signaling pathway, by which resveratrol executes
its inhibitory effect on TNF-β-signaling pathway, we investigated whether NF-κB and NF-κB-
regulated gene end-products involved in inflammation, proliferation and apoptosis were acti-
vated. We found that resveratrol significantly suppressed NF-κB activation induced by TNF-β
and/or T-lymphocytes in chondrocytes. NF-κB suppression correlated with reduced p65 phos-
phorylation and nuclear translocation. Furthermore, resveratrol also down-regulated NF-κB
dependent gene end-products involved in cell proliferation (e.g. Ki67), inflammatory (COX-
2), in matrix degrading (MMP-9/-13) and apoptotic (cleaved caspase-3) signaling pathways
induced by TNF-β- or T-lymphocytes. Interestingly, the inhibition effect of resveratrol was, at
least in part, Sirt1-signalling dependent. Resveratrol’s inhibition of the NF-κB activation
induced by TNF-β and/or T-lymphocytes suggests that resveratrol/Sirt1 signaling acts at a step
common to all of these activators. However, we are the first to report the ability of resveratrol
to modulate expression and activation of TNF-β in chondrocytes and TNF-β-induced RA-
microenvironment. These results suggest that the effects of resveratrol on TNF-β signaling are,
at least in part, through suppression of NF-κB signaling in chondrocytes.
We further found that treatment of chondrocytes with ASO-Sirt1, like NAM or TNF-β,
caused NF-κB activation and up-regulation of NF-κB-related gene end-products involved in
degradation, inflammation and apoptosis (MMP-9/-13, COX-2 expression, caspase-3 cleav-
age) and this was accompanied by the decreased synthesis of cartilage-specific matrix, Ki67,
Sirt1 and Sox9 expression. However, co-treatment with resveratrol inhibited NF-κB activation
and NF-κB-related gene end-products by NAM, TNF-β or T-lymphocytes and revealed a
Fig 10. Schematic diagram illustrating TNF-β-induced up-regulation of pro-inflammatory, apoptotic
signaling and suppression of cell viability, chondrogenic markers modulated by resveratrol-Sirt1
signaling pathways.
https://doi.org/10.1371/journal.pone.0186993.g010
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significant increasing in cartilage-specific matrix expression, Ki67, Sirt1 and Sox9 expression,
but not by Sirt1-ASO. These results show clearly that TNF-β-mediated NF-κB activation in
chondrocytes is similar to Sirt1-ASO or NAM, indicating that Sirt1 is one of the main down-
stream signaling molecules for TNF-β-signaling that may be modulated by resveratrol-medi-
ated signaling pathways in RA inflammatory microenvironment. Moreover, these findings
clearly indicate that down-regulation of Sirt1 by mRNA interference abrogates the suppressive
effects of resveratrol on TNF-β- and NF-κB signaling, highlighting the important role and
function of Sirt1 for anti-inflammatory and anti-cytokine pathway of resveratrol in RA/OA
inflammatory joint environment.
Conclusions
In conclusion, our study here demonstrates for the first time that TNF-β induces a pro-inflam-
matory microenvironment similar to TNF-α and T-lymphocytes, up-regulating pro-inflam-
matory signaling and suppressing chondrogenic potential in primary human chondrocytes.
Further, we could demonstrate that resveratrol-mediated Sirt1 up-regulation inhibits TNF-β-
induced pro-inflammatory and degenerative pathways in chondrocytes (Fig 10). Thus, target-
ing TNF-β might be a novel and promising therapeutic approach for improving and support-
ing anti-inflammatory therapy in RA/OA.
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